Expanding Global Collaboration in Severe Asthma: Highlights from the ISAR Industry Symposium On 27 September 2025, the International Severe Asthma Registry (ISAR) hosted its first industry-wide symposium, welcoming representatives from multiple countries, leading pharmaceutical companies, and research organisations. This milestone event marked ISAR’s transition from a single industry funded initiative to a truly global, multi-partner collaboration. Driving Impact Through Data

The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα)  was associated

A novel Bayesian Network analysis on the International Severe Asthma Registry (ISAR) has identified key clinical and biological pathways...

The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...

Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...

New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...